Results 31 to 40 of about 2,201,777 (199)

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

The Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi, Alessandra Ferro, Fabiana Cecere, Daniela Scattolin, Alessandro Del Conte, Alessandro Follador, Sara Pilotto, Valentina Polo, Mariacarmela Santarpia, Rita Chiari, Alberto Pavan, Alessandro Dal Maso, Valentina Da Ros, Giada Targato, Sabrina Vari, Stefano Indraccolo, Fiorella Calabrese, Stefano Frega, Laura Bonanno, Pier Franco Conte, Valentina Guarneri, Giulia Pasello   +21 more
wiley   +1 more source

Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer

Cancer Cell International, 2021
Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations will inevitably develop drug resistance after being treated with the third-generation EGFR-tyrosine kinase inhibitor (TKI), osimertinib ...
Xinying Li, Cen Chen, Zimu Wang, Jiaxin Liu, Wei Sun, Kaikai Shen, Yanling Lv, Suhua Zhu, Ping Zhan, Tangfeng Lv, Yong Song   +10 more
doaj   +1 more source

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

Respiratory Research, 2021
Background This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI ...
Changhui Li, Wei Nie, Jingdong Guo, Anning Xiong, Hua Zhong, Tianqing Chu, Runbo Zhong, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Bo Zhang, Yinchen Shen, Feng Pan, Baohui Han, Xueyan Zhang   +14 more
doaj   +1 more source

Мechanisms of Acquired Resistance to Osimertinib

Voprosy onkologii, 2023
Осимертиниб — препарат выбора первой линии терапии больных немелкоклеточным раком легкого (НМРЛ) с активирующими мутациями в гене рецептора эпидермального фактора роста (epidermal growth factor receptor — EGFR) и стандарт второй линии для пациентов с мутацией резистентности Т790М после прогрессирования на ингибиторах тирозинкиназ (ИТК) EGFR первого и ...
openaire   +1 more source

Can We Prevent Resistance to Osimertinib? Combination or Sequential [PDF]

Journal of Thoracic Oncology, 2018
restriction
Min Hwan, Kim, Sun Min, Lim, Kwangho, Lee, Ross Andrew, Soo, Byoung Chul, Cho   +4 more
openaire   +3 more sources

Primary resistance to osimertinib despite acquired T790M

Respirology Case Reports, 2020
Current National Comprehensive Cancer Network (NCCN) guidelines suggest plasma‐based testing (liquid biopsy) for T790M in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung carcinoma (NSCLC) with acquired resistance to first‐/second‐generation EGFR tyrosine kinase inhibitors (TKIs).
Ling‐Kai Chang, Yih‐Leong Chang, Jin‐Yuan Shih   +2 more
openaire   +3 more sources

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Journal of Hematology & Oncology, 2022
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations.
Kai Fu, Fachao Xie, Fang Wang, Liwu Fu
doaj   +1 more source

CZC54252 overcomes Osimertinib resistance by targeting EGFR^C797S mutations. [PDF]

BMC Pharmacol Toxicol
Ma T, Yuan T, Hou Y, Liu M, Zhang Y, Shi J, Zhong L.   +6 more
europepmc   +2 more sources

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments

Clinical Medicine Insights: Oncology, 2022
Background: Although the clinical application of osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been a new step forward in the first-line treatment of non-small cell lung cancer (NSCLC), an ...
Naifu Nie, Jianghua Li, Jian Zhang, Jie Dai, Zhulin Liu, Zhenyu Ding, Yubo Wang, Mengxiao Zhu, Chen Hu, Rui Han, Huan Tang, Li Li, Yong He   +12 more
doaj   +1 more source

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Molecular Cancer, 2021
Background Epidermal growth factor receptor (EGFR)-mutated lung cancer constitutes a major subgroup of non-small cell lung cancer (NSCLC) and osimertinib is administrated as first-line treatment.
Shaocong Wu, Min Luo, Kenneth K. W. To, Jianye Zhang, Chaoyue Su, Hong Zhang, Sainan An, Fang Wang, Da Chen, Liwu Fu   +9 more
doaj   +1 more source